3-unsubstituted N-(arylor heteroarvl)-pyrazolori [1,5-a]pyrimidines as kinase inhibitors

Details for Australian Patent Application No. 2007233926 (hide)

Owner Novartis AG

Inventors Vaupel, Andrea; Imbach, Patricia; Masuya, Keiichi; Furet, Pascal

Agent Davies Collison Cave

Pub. Number AU-A-2007233926

PCT Pub. Number WO2007/112998

Priority 0606804.3 04.04.06 GB

Filing date 2 April 2007

Wipo publication date 11 October 2007

International Classifications

C07D 487/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

Event Publications

16 October 2008 PCT application entered the National Phase

  PCT publication WO2007/112998 Priority application(s): WO2007/112998

2 April 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read 3-unsubstituted N-(arylor heteroaryl)-pyrazolori [1,5-a]pyrimidines as kinase inhibitors

16 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007233928-3-substituted N-(arylor heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors

2007233921-Method for producing propene from propane